EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting

Wichai Termrungruanglert iD, Nipon Khemapech iD, Apichai Vasuratna iD, Piyalamporn Havanond iD, Tanitra Tantitamit iD

Journal of Gynecologic Oncology · 2024

DOI: 10.3802/jgo.2024.35.e85 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Wichai Termrungruanglert und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Papillomavirus Vaccines, Papillomavirus Infections, Quality-Adjusted Life Years. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSP VA, Chulalongkorn University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To compare the health impact and economic benefits among individuals who did not receive the human papillomavirus (HPV) vaccine to those who received a single dose, or 2 doses. The comparison was stratified by 4 types of vaccine in conjunction with primary HPV screening in a low/middle-income country setting. METHODS: A Markov model was employed to simulate HPV infection and cervical cancer in a cohort of 100,000 12-year-old girls free of HPV. The study scrutinized 9 strategies: 1 dose and 2 doses of 2vHPV (Cervarix®), 2vHPV (Cecolin®), 4vHPV (Gardasil®), 9vHPV vaccine (Gardasil9®), and no vaccination. The primary outcome measure was the quality-adjusted life year (QALY) of each strategy. Incremental cost-effectiveness ratios were estimated over a lifetime horizon, accompanied by sensitivity analyses conducted. RESULTS: All vaccination programs yielded 41,298-71,057 QALYs gained accompanied by cost savings of 14,914,186-19,821,655 USD compared to no vaccination. Administering 2 doses of 9vHPV vaccine emerged as the most cost-effective strategy, boasting 406 USD/QALY, within a lower willingness to pay threshold. Sensitivity analysis demonstrated an 80% probability of the cost-effectiveness of the 2 doses of 9vHPV vaccine regimen. Furthermore, uncertainty around the costs of vaccination and vaccine efficacy exerted the most substantial influence on the cost-effectiveness findings. CONCLUSION: Oping for 2 doses of 9vHPV vaccine in conjunction with a primary HPV screening represents the most cost-effective option for implementing a school-based HPV vaccination program targeting 12-year-old girls in Thailand. Such findings provide valuable insights for policymakers in the realm of cervical cancer prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisPapillomavirus VaccinesPapillomavirus InfectionsQuality-Adjusted Life YearsMarkov ChainsUterine Cervical NeoplasmsHumansFemaleChildDeveloping CountriesHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Cost-Effectiveness Analysis

Stichwörter der Autor:innen

Cost-Effectiveness AnalysisHuman PapillomavirusLower-Middle-Income CountryQuality-Adjusted Life YearsUterine Cervical NeoplasmsVaccination

Substanzen

Papillomavirus VaccinesHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Department of Obstetrics and Gynecology, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok, Thailand. ttanitra@gmail.com.

ORCID-Profile: Wichai Termrungruanglert, Nipon Khemapech, Apichai Vasuratna, Piyalamporn Havanond, Tanitra Tantitamit

Förderung

  • CSP VA
  • Chulalongkorn University

Zitieren

APA

Termrungruanglert, W., Khemapech, N., Vasuratna, A., Havanond, P., & Tantitamit, T. (2024). Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e85

Vancouver

Termrungruanglert W, Khemapech N, Vasuratna A, Havanond P, Tantitamit T. Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e85

BibTeX
@article{Termrungruanglert2024,
  author = {Termrungruanglert, Wichai and Khemapech, Nipon and Vasuratna, Apichai and Havanond, Piyalamporn and Tantitamit, Tanitra},
  title = {Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low/middle-income country setting},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  doi = {10.3802/jgo.2024.35.e85}
}
Kostenlos starten →